PI3K: A potential therapeutic target for cancer

Journal of Cellular Physiology

Volumn 227, Issue 7, 2012, Pages 2818-2821

  Chen, Yingwei ^a,b   Wang, Bao Can ^a   Xiao, Yongtao ^b  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b Shanghai Institute of Pediatric Research   (China)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 DIALLYLAMINOMETHYLENE 1,3,4,7,10,11,12,13,14,15,16,17 DODECAHYDRO 6 HYDROXY 1 METHOXYMETHYL 10,13 DIMETHYL 3,7,17 TRIOXO 2 OXACYCLOPENTA[A]PHENANTHREN 11 YL ACETATE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE GAMMA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN P28; TRANSFORMING GROWTH FACTOR BETA; VIMENTIN; WORTMANNIN;

ANTINEOPLASTIC ACTIVITY; AUTOPHAGY; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CANCER INVASION; CARCINOGENESIS; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; CELL VACUOLE; CHROMOSOME 10; CLINICAL TRIAL (TOPIC); CRYSTAL STRUCTURE; DIGESTIVE SYSTEM CANCER; DRUG BIOAVAILABILITY; DRUG SOLUBILITY; DRUG TARGETING; EMBRYO DEVELOPMENT; ENDOMETRIUM CANCER; EPITHELIAL MESENCHYMAL TRANSITION; GOLGI COMPLEX; HUMAN; HUMAN HERPESVIRUS 8; IC 50; LIVER CELL CARCINOMA; METASTASIS; NEOPLASM; POINT MUTATION; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; SENESCENCE; SHORT SURVEY; SIGNAL TRANSDUCTION; URINARY TRACT CANCER;

ANIMALS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASE; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION;

EID: 84863337700     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.23038     Document Type: Short Survey

References (40)

1. Arcaro A, Wymann MP. 1993. Wortmannin is a potent phosphatidylinositol 3-kinase inhibitor: The role of phosphatidylinositol 3, 4, 5-trisphosphate in neutrophil responses. Biochem J 296: 297-301.
2. Arico S, Petiot A, Bauvy C, Dubbelhuis PF, Meijer AJ, Codogno P, Ogier-Denis E. 2001. The tumor suppressor PTEN positively regulates macroautophagy by inhibiting the phosphatidylinositol 3-kinase/protein kinase B pathway. J Biol Chem 276: 35243-35246.
3. Backer JM. 2008. The regulation and function of Class III PI3Ks: Novel roles for Vps34. Biochem J 410: 1-17.
4. Botti J, Djavaheri-Mergny M, Pilatte Y, Codogno P. 2006. Autophagy signaling and the cogwheels of cancer. Autophagy 2: 67-73.
5. Bowles DW, Jimeno A. 2011. New phosphatidylinositol 3-kinase inhibitors for cancer. Expert Opin Invest Drugs 20: 507-518.
6. Cantley LC. 2002. The phosphoinositide 3-kinase pathway. Science 296: 1655-1657.
7. Carson JD, Van Aller G, Lehr R, Sinnamon RH, Kirkpatrick RB, Auger KR, Dhanak D, Copeland RA, Gontarek RR, Tummino PJ, Luo L. 2008. Effects of oncogenic p110alpha subunit mutations on the lipid kinase activity of phosphoinositide 3-kinase. Biochem J 409: 519-524.
8. Chiarugi P, Cirri P, Taddei ML, Talini D, Doria L, Fiaschi T, Buricchi F, Giannoni E, Camici G, Raugei G, Ramponi G. 2002. New perspectives in PDGF receptor downregulation: The main role of phosphotyrosine phosphatases. J Cell Sci 115: 2219-2232.
9. Engelman JA, Luo J, Cantley LC. 2006. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 7: 606-619.
10. Fu J, Chen Y, Cao J, Luo T, Qian YW, Yang W, Ren YB, Su B, Cao GW, Yang Y, Yan YQ, Shen F, Wu MC, Feng GS, Wang HY. 2011. p28(GANK) overexpression accelerates hepatocellular carcinoma invasiveness and metastasis via phosphoinositol 3-kinase/AKT/hypoxia-inducible factor-1alpha pathways. Hepatology 1: 181-192.
11. Gallia GL, Rand V, Siu IM, Eberhart CG, James CD, Marie SK, Oba-Shinjo SM, Carlotti CG, Caballero OL, Simpson AJ, Brock MV, Massion PP, Carson BS Sr, Riggins GJ. 2006. PIK3CA gene mutations in pediatric and adult glioblastoma multiforme. Mol Cancer Res 4: 709-714.
12. Hu L, Zaloudek C, Mills GB, Gray J, Jaffe RB. 2000. In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002). Clin Cancer Res 6: 880-886.
13. Huang CH, Mandelker D, Schmidt-Kittler O, Samuels Y, Velculescu VE, Kinzler KW, Vogelstein B, Gabelli SB, Amzel LM. 2007. The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations. Science 318: 1744-1748.
14. Katso R, Okkenhaug K, Ahmadi K, White S, Timms J, Waterfield MD. 2001. Cellular function of phosphoinositide 3-kinases: Implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol 17: 615-675.
15. Kazlauskas A, Kashishian A, Cooper JA, Valius M. 1992. GTPase-activating protein and phosphatidylinositol 3-kinase bind to distinct regions of the platelet-derived growth factor receptor beta subunit. Mol Cell Biol 12: 2534-2544.
16. Ke AW, Shi GM, Zhou J, Huang XY, Shi YH, Ding ZB, Wang XY, Devbhandari RP, Fan J. 2011. CD151 amplifies signaling by integrin alpha6beta1 to PI3K and induces the epithelial-mesenchymal transition in HCC cells. Gastroenterology 140: 1629-1641.
17. Kennedy AL, Morton JP, Manoharan I, Nelson DM, Jamieson NB, Pawlikowski JS, McBryan T, Doyle B, McKay C, Oien KA, Enders GH, Zhang R, Sansom OJ, Adams PD. 2011. Activation of the PIK3CA/AKT pathway suppresses senescence induced by an activated RAS oncogene to promote tumorigenesis. Mol Cell 42: 36-49.
18. Kondo Y, Kanzawa T, Sawaya R, Kondo S. 2005. The role of autophagy in cancer development and response to therapy. Nat Rev Cancer 5: 726-734.
19. Martin D, Galisteo R, Molinolo AA, Wetzker R, Hirsch R, Gutkind JS. 2011. PI3Kgamma mediates kaposi's sarcoma-associated herpesvirus vGPCR-induced sarcomagenesis. Cancer Cell 19: 805-813.
20. Murugan AK, Hong NT, Fukui Y, Munirajan AK, Tsuchida N. 2008. Oncogenic mutations of the PIK3CA gene in head and neck squamous cell carcinomas. Int J Oncol 32: 101-111.
21. Nakanishi S, Kakita S, Takahashi I, Kawahara K, Tsukuda E, Sano T, Yamada K, Yoshida M, Kase H, Matsuda Y, Hashimot Y, Nonomuran Y. 1992. Wortmannin, a microbial product inhibitor of myosin light chain kinase. J Biol Chem 267: 2157-2163.
22. Naumann P, Fortunato F, Zentgraf H, Buchler MW, Herr I, Werner J. 2011. Autophagy and cell death signaling following dietary sulforaphane act independently of each other and require oxidative stress in pancreatic cancer. Int J Oncol 39: 101-109.
23. Nobukuni T, Joaquin M, Roccio M, Dann SG, Kim SY, Gulati P, Byfield MP, Backer JM, Natt F, Bos JL, Zwartkruis FJ, Thomas G. 2005. Amino acids mediate mTOR/raptor signaling through activation of class 3 phosphatidylinositol 3OH-kinase. Proc Natl Acad Sci USA 102: 14238-14243.
24. Odorizzi G, Babst M, Emr SD. 2000. Phosphoinositide signaling and the regulation of membrane trafficking in yeast. Trends Biochem Sci 25: 229-235.
25. Pang H, Flinn R, Patsialou A, Wyckoff J, Roussos ET, Wu H, Pozzuto M, Goswami S, Condeelis JS, Bresnick AR, Segall JE, Backer JM. 2009. Differential enhancement of breast cancer cell motility and metastasis by helical and kinase domain mutations of class IA phosphoinositide 3-kinase. Cancer Res 69: 8868-8876.
26. Petiot A, Ogier-Denis E, Blommaart EF, Meijer AJ, Codogno P. 2000. Distinct classes of phosphatidylinositol 3'-kinases are involved in signaling pathways that control macroautophagy in HT-29cells. J Biol Chem 275: 992-998.
27. Powis G, Bonjouklian R, Berggren MM, Gallegos A, Abraham R, Ashendel C, Zalkow L, Matter WF, Dodge J, Grindey G, Vlahos CJ. 1994. Wortmannin, a potent and selective inhibitor of phosphatidylinositol-3-kinase. Cancer Res 54: 2419-2423.
28. Riener MO, Bawohl M, Clavien PA, Jochum W. 2008. Rare PIK3CA hotspot mutations in carcinomas of the biliary tract. Genes Chromosomes Cancer 47: 363-367.
29. Singh A, Settleman J. 2010. EMT, cancer stem cells and drug resistance: An emerging axis of evil in the war on cancer. Oncogene 29: 4741-4751.
30. Stephens LR, Eguinoa A, Erdjument-Bromage H, Lui M, Cooke F, Coadwell J, Smrcka AS, Thelen M, Cadwallader K, Tempst P, Hawkins PT. 1997. The G beta gamma sensitivity of a PI3K is dependent upon a tightly associated adaptor, p101. Cell 89: 105-114.
31. Sugimoto Y, Whitman M, Cantley LC, Erikson RL. 1984. Evidence that the Rous sarcoma virus transforming gene product phosphorylates phosphatidylinositol and diacylglycerol. Proc Natl Acad Sci USA 81: 2117-2121.
32. Toker A, Cantley LC. 1997. Signalling through the lipid products of phosphoinositide-3-OH kinase. Nature 387: 673-676.
33. Vanhaesebroeck B, Leevers SJ, Ahmadi K, Timms J, Katso R, Driscoll PC, Woscholski R, Parker PJ, Waterfield MD. 2001. Synthesis and function of 3-phosphorylated inositol lipids. Annu Rev Biochem 70: 535-602.
34. Walker EH, Pacold ME, Perisic O, Stephens L, Hawkins PT, Wymann MP, Williams RL. 2000. Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol Cell 6: 909-919.
35. Wang SE, Xiang B, Guix M, Olivares MG, Parker J, Chung CH, Pandiella A, Arteaga CL. 2008. Transforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab. Mol Cell Biol 28: 5605-5620.
36. Whitman M, Kaplan DR, Schaffhausen B, Cantley L, Roberts TM. 1985. Association of phosphatidylinositol kinase activity with polyoma middle-T competent for transformation. Nature 315: 239-242.
37. Zhang SQ, Tsiaras WG, Araki T, Wen G, Minichiello L, Klein R, Neel BG. 2002. Receptor-specific regulation of phosphatidylinositol 3′-kinase activation by the protein tyrosine phosphatase Shp2. Mol Cell Biol 22: 4062-4072.
38. Zhang X, Vadas O, Perisic O, Anderson KE, Clark J, Hawkins PT, Stephens LR, Williams RL. 2011. Structure of lipid kinase p110beta/p85beta elucidates an unusual SH2-domain-mediated inhibitory mechanism. Mol Cell 41: 567-578.
39. Zhao TT, Trinh D, Addison CL, Dimitroulakos J. 2010. Lovastatin inhibits VEGFR and AKT activation: Synergistic cytotoxicity in combination with VEGFR inhibitors. PLoS ONE 5: e12563.
40. Zhu QS, Rosenblatt K, Huang KL, Lahat G, Brobey R, Bolshakov S, Nguyen T, Ding Z, Belousov R, Bill K, Luo X, Lazar A, Dicker A, Mills GB, Hung MC, Lev D. 2011. Vimentin is a novel AKT1 target mediating motility and invasion. Oncogene 30: 457-470.